

WYDUR Board Meeting Minutes
Thursday, November 17, 2005
Wyoming Petroleum Club
Casper, Wyoming
11a.m.-3p.m.

Members Present: Mike Carpenter, William Harrison, Kurt Hopfensperger, George Zaharas, Roxanne Homar, Donna Artery, Aimee Lewis, Bill Keenan, Dean Winsch, Richard Johnson, Becky Drnas, Antoinette Brown, Deb Devereaux (by teleconference)

Members Excused: Scott Johnston, Kevin Robinett

Guests: Randy Becker (Merck), Donna Artery (Dept of Health Intern), Dave Jones (Amgen), Terry Ahlers (Pfizer), Pierre Thoumsin (Amgen), Betty Iverson (Wyeth) by teleconference, Tim Hynek (Lilly), John Spear (Lilly), Justin French (Sepracor)

I. Members were introduced and there were no announcements.

II. The minutes of the September 29, 2005 meeting were approved as presented.

III. Department of Health

Criteria will be updated on all prior authorization forms to include the following-"unable to tolerate or unacceptable side effects to preferred agent(s)". Adult ADHD preferred list implementation deferred until smart PA installation in spring 2006.

Medicare Part D-Dual eligibles are being transitioned and auto enrolled to Prescription Drug Plans. Wyoming will wrap around benzodiazepines, barbiturates and OTC products currently covered in the Wyoming Medicaid program. The clawback number for Wyoming is \$10 million yearly. Systems testing is currently underway to make sure that all duals are enrolled in a plan. Education and outreach have been a joint effort of AARP and the WSHEP programs. There are LTC facilities issues. The CMS plan finder is working intermittently. The benchmark is Wyoming is \$33.11 per month. Pharmacies do not know reimbursement rates yet. The Dept of Health will be putting together a one page sheet for providers with PDPs and MA-PDs for Wyoming, telephone numbers and website URLs. Humana has a \$1 per month plan which includes no drugs.

IV. New Business

Updates on the Multiple Sclerosis and prediabetes projects were received. We are working with HID to identify study parameters for the mental health utilization project.

The Board reviewed utilization figures for the stimulants and discussed increasing the prescription amount to 90 days. Jim Caarder and the State Board of Pharmacy regs will be consulted as well as any specific DEA restrictions.

The letter advising providers of the increased mortality risk with atypical antipsychotic use in the elderly was sent. The Board suggested that the specific concerns be bolded in the letter on the web-site.

Scott is working on the narcotic maximum limits letter to providers.

The preferred PPIs will remain the same. Solutabs will be approved on a case by case basis.

The Board requested that APS present their published cost savings information at the January WYDUR meeting specifically addressing the details of the reported \$15 million savings including details by diagnosis, numbers of patients and case management results.

The Board also requested that a review of patients seeing 5 or more providers be conducted yearly and feedback solicited from those providers.

V. Old Business

Newsletter suggestions-legislative information, Part D implementation, diabetic neuropathy drugs.

VI. Open Comments

No open comments were received.

VII. Prospective and retrospective DUR

Delete criteria #604.

Several provider issues were discussed and education strategies were devised.

There being no further business, the meeting was adjourned at 2:35p.m.

Respectfully Submitted,

Debra Devereaux MBA, R.Ph.
Wyoming DUR Manager